TCP has very low acute toxicity, but it is transformed in the body to a highly toxic metabolite. In humans, the first symptoms are weakness/paralysis of the hands and feet on both sides of the body due to damage to the peripheral nervous system (
polyneuropathy) and a sensation of pins-and-needles (
paresthesia). Onset typically occurs between 3–28 days from initial exposure. Exposure to TOCP has been characterized by a list of observations: Mammalian placental development were also negatively affected. This metabolite is able to inhibit
neuropathy target esterase (NTE) and results in the classic organophosphate-induced delayed neuropathy (
OPIDN). In tandem, TOCP exerts physical damage by causing
axonal destruction and
myelin disintegration within specialized cells that transmit nerve impulses (
neurons). In addition to the formation of SCOTP, the interactions between TOCP and two different human cytochrome P450 complexes (
1A2 and
3A4) can further produce 2-(
ortho-cresyl)-4
H-1,2,3-benzodioxaphosphoran-2-one (CBDP). This metabolite can bind to
butyrylcholinesterase (BuChE) and/or
acetylcholinesterase (AChE). Binding to BuChE results in no adverse effects, for its typical role is to covalently bind to organophosphate poisons and detoxify them by inactivation. The dangers in metabolizing TOCP to CBDP occur when its potential to bind to AChE become imminent, for inactivation of the enzyme in nerve synapses can be lethal. The enzyme plays a tantamount role in terminating nerve impulse transmission "by hydrolyzing the neurotransmitter acetylcholine." Upon inactivation,
acetylcholine can no longer be broken down in the body and results in uncontrollable muscle spasms, paralyzed breathing (
bradycardia), convulsions, and/or death. Luckily, TOCP is considered a weak AChE inhibitor. ==Health calamities from TCP==